Epix Pharmaceuticals
Epix Pharmaceuticals Inc (formerly Predix Pharmaceuticals Inc) was a pharmaceutical company based in Lexington, Massachusetts.
Its products included the following agents:
- PRX-00023—5-HT1A receptor full agonist (later discovered to actually be an antagonist): for major depression and generalized anxiety disorder
- PRX-03140—5-HT4 receptor partial agonist: for Alzheimer's disease
- PRX-07034—5-HT6 receptor antagonist: for obesity and cognitive impairment associated with Alzheimer's disease and schizophrenia
- PRX-08066—5-HT2B receptor antagonist: for pulmonary hypertension associated with chronic obstructive pulmonary disease
As of July 2009, the company was in the process of asset liquidation due to insufficient funds to stay afloat.[1]
References
- ↑ Weisman, Robert (22 July 2009). "Epix Pharmaceuticals of Lexington is latest biotech to fall to funding crunch". The Boston Globe. Retrieved 23 November 2011.
External links
This article is issued from Wikipedia - version of the 5/16/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.